Preclinical lupus

Current Opinion in Rheumatology

Volumn 27, Issue 5, 2015, Pages 433-439

  Bourn, Rebecka ^a   James, Judith A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Incomplete lupus; Latent lupus; Preclinical; Systemic lupus erythematosus

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; ANTIMALARIAL AGENT; AZATHIOPRINE; BIOLOGICAL PRODUCT; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYCHLOROQUINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOGLOBULIN; LEFLUNOMIDE; METFORMIN; METHOTREXATE; MYCOPHENOLATE MOFETIL; RITUXIMAB; ROSIGLITAZONE; SALAZOSULFAPYRIDINE;

AUTOIMMUNITY; CLINICAL FEATURE; CLINICAL OBSERVATION; CLINICAL TRIAL (TOPIC); CORTICOSTEROID THERAPY; DISEASE CLASSIFICATION; DIURETIC THERAPY; HIGH RISK PATIENT; HUMAN; IMMUNE DYSREGULATION; INCOMPLETE LUPUS ERYTHEMATOSUS; INTERVENTION STUDY; LUPUS ERYTHEMATOSUS; MEDICAL TERMINOLOGY; NONHUMAN; PATHOGENESIS; PLASMAPHERESIS; PREDICTOR VARIABLE; PREVENTION STUDY; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; SYSTEMIC LUPUS ERYTHEMATOSUS; CLASSIFICATION; EARLY DIAGNOSIS; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EARLY DIAGNOSIS; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 84942587974     PISSN: 10408711     EISSN: 15316963     Source Type: Journal    
DOI: 10.1097/BOR.0000000000000199     Document Type: Review

References (51)

1. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 1982; 25:1271-1277.
2. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthr Rheum 1997; 40:1725.
3. Petri M, Orbai AM, Alarcon GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupu s erythematosus. Arthr Rheum 2012; 64:2677-2686.
4. Ganczarczyk L, Urowitz MB, Gladman DD. Latent lupus. J Rheumatol 1989; 16:475-478.
5. Greer JM, Pa nush RS. Incomplete lupus erythematosus. Arch Intern Med 1989; 149:2473-2476.
6. Vila LM, Mayor AM, Valentin AH, et al. Clinical outcome and predictors of disease evolution in patients with incomplete lupus erythematosus. Lupus 2000; 9:110-115.
7. Stahl Hallengren C, Nived O, Sturfelt G. Outcome of incomplete systemic lupus erythematosus after 10 years. Lupus 2004; 13:85-88.
8. Laustrup H, Voss A, Green A, Junker P. Occurrence of systemic lupus erythematosus in a Danish community: an 8-year prospective study. Scand J Rheumatol 2009; 38:128-132.
9. Olsen NJ, Li QZ, Quan J, et al. Autoantibody profiling to follow evolution of lupus syndromes. Arthr Res Ther 2012; 14:R174.
10. Fabio G, Carrabba M, Hu C, et al. Dramatic development of severe SLE in a patient with an incomplete disease. Rheumatol Int 2005; 25:543-547.
11. Olsen NJ, Karp DR. Autoantibodies and SLE: the threshold for disease. Nature Rev Rheumatol 2014; 10:181-186. This article summarizes the current findings on the presence of SLE-Associated antibodies in healthy individuals and discusses what these studies may predict about the role of autoantibodies in disease deve lopment.
12. Robertson JM, James JA. Preclinical systemic lupus erythematosus. In: Bykerk VP, Costenbader KH, Deane KH, editors. Preclinical rheumatic disease. Philadelphia, Pennsylvania:: Elsevier; 2014. p. 822 . This chapter reviewsautoantibody specificities and serologic markers observed prior to SLEclassification, as well as characteristics of patientswho transition to SLE. Also refer to the chapter 'Preclinical Inflammatory Rheumatic Diseases: An Overvie w and Relevant Nomenclature' by K. Raza and D.M. Gerlag for an overview of current perspectives on the early stages of various autoimmune rheumatic diseases.
13. Rua-Figueroa I, Richi P, Lopez-Longo FJ, et al. Comprehensive description of clinical characteristics of a large systemic lupus erythematosus cohort from the Spanish Rheumatology Society Lupus Registry (RELESSER) with emphasis on compl ete versus incomplete lupus differences. Medicine 2015; 94:e267. This study identifies differences between SLE and ILE in a group of patients from the Spanish Rheumatology Society SLE Registry (RELESSER). This article highlights the largest European SLE registry compiled to date and identifies ILE as a relatively stable, mild form of the disease.
14. Chen Z, Li MT, Xu D, et al. Organ damage in patients with incomplete lupus syndromes: from a Chinese academic cent er. Clin Rheumatol 2015. doi: 10.1007/s10067-015-2884-3. This study evaluated organ damage associated with incomplete lupus syndromes using the SLICC/ACR Damage Index. This article shows a subset of ILE patients are likely to have organ damage, espec ially patients of older age.
15. Al Daabil M, Massarotti EM, Fine A, et al. Development of SLE among ' potential SLE' patients seen in consultation: long-term follow-up. Int J Clin Pract 2014; 68:15 08-1513. This study followed a group of 'potential' SLE patients for an average of 6 years and identified oral ulcers, anti-dsDNA, and baseline proteinuria or cellular casts as predictors of SLE development. These observations will be important for early identification of individuals at a higher risk for development of SLE.
16. Olsen NJ,Yousif M,Mutwally A,et al. Organ damage in high-risk patients with systemic and incomplete lupus syndromes Rheumatol Int 2013, 33, 2585-2590.
17. James JA, Kim-Howard XR, Bruner BF, et al. Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 2007; 16:401-409.
18. Heinlen LD, McClain MT, Merrill J, et al. Clinical criteria for systemic lupus erythematosus precede diagnosis, and associated autoantibodies are present before clinical symptoms. Arthr Rheum 200 7; 56:2344-2351.
19. Arbuckle MR, McClain MT, Rubertone MV, et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349:1526-1533.
20. Li QZ, Karp DR, Quan J, et al. Risk factors for ANA positivity in healthy persons. Arthr Res Ther 2011; 13:R38.
21. Wandstrat AE, Carr-Johnson F, Branch V, et al. Autoantibody profiling to identify individuals at risk for systemic lupus erythematosus. J Autoimmun 2006; 27:153-160.
22. Mariz HA, Sato EI, Barbosa SH, et al. Pattern on the antinuclear antibody-HEp-2 test is a critical parameter for discriminating antinuclear antibodypositive healthy individuals and patients with autoimmune rheumatic diseases. Arthr Rheum 2011; 63:191-200.
23. Satoh M,Chan EK,HoLA, et al. Prevalence and sociodemographic correlates of antinuclear antibodies in the United States. Arthr Rheum 2012; 64:2319-2327.
24. Mosca M, Tani C, Bombardieri S. Defining undifferentiated connective tissue diseases: a challenge for rheumatologists. Lupus 2008; 17:278-280.
25. Mosca M, Neri R, Bombardieri S. Undifferentiated connective tissue diseases (UCTD): a review of the literature and a proposal for preliminary classification criteria. Clin Exp Rheumatol 1999; 17:615-620.
26. Mosca M, Tani C, Car li L, Bombardieri S. Undifferentiated CTD: a wide spectrum of autoimmune diseases. Best Pract Res Clin Rheumatol 2012; 26:73-77.
27. Szodoray P, Nakken B, Barath S, et al. Altered T h17 cells and Th17/regulatory T-cell ratios indicate the subsequent conversion from undifferentiated connective tissue disease to definitive systemic autoimmune disorders. Human Immunol 2013; 74:1510-1518.
28. G uerrero LF, Rueda JC, Arciniegas R, Rueda JM. Undifferentiated connective tissue disease in a rheumatology center in Cali, Colombia: clinical features of 94 patients followed for a year. Rheumatol Int 2013; 33:1085-1 088.
29. Jung JY, Koh BR, Kim HA, et al. Autoantibodies to C-reactive protein in incomplete lupus and systemic lupus erythematosus. J Investig Med 2014; 62:890-893.
30. Quan J, Lakhanpal A, Reddy MM, et al. Discovery of biomarkers for systemic lupus erythematosus using a library of synthetic autoantigen surrogates. J Immunol Meth 2014; 402 (1-2):23-34. In this study, complex libraries of nonamers consis t ing of N-substituted glycines (peptoids) were probed for compounds that bound IgG from patients with SLE, as well as earlier, incomplete autoimmune syndromes. The synthetic peptoids were able to detect IgG classes found in disease and could potentially be used to classify individuals with SLE. These data indicate a potential new way to identify patients with higher levels of pathogenic autoantibodies.
31. Dellavance A, Coelho Andrade LE. Immunologic derangement preceding clinical autoimmunity. Lupus 2014; 23:1305-1308.
32. Venegas-Pont M, Sartori-Valinotti JC, Maric C, et al. Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus. Am J Physiol Regul Integr Comparat Physiol 2009; 296:R1282-R1289.
33. Aprahamian TR, Bonegio RG, Weitzner Z, et al. Peroxisome proliferatoractivated receptor gamma agonists in the prevention and treatment of murine systemic lupus erythematosus. Immunology 2014; 142:363-373. This study evaluated the effects of PPAR-g agonist treatment during early or established disease in multiple mouse models of lupus.
34. Aprahamian T, Bonegio RG, Richez C, et al. The peroxisome proliferatoractivated receptor gamma agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 2009; 182:340-346.
35. Yin Y, Choi SC, Xu Z, et al. Normalization of CD4+ T cell metabolism reverses lupus. Sci Transl Med 2015; 7:274ra18. This study evaluated the effects of metformin treatment on disease progression in lupus-prone mice.
36. Rowland SL, Riggs JM, Gilfillan S, et al. Early, transient depletion of plasmacytoid dendritic cells ameliorates autoimmunity in a lupus model. J Exp Med 2014; 211:1977-1991. This study found plasmacytoid dendritic cells to be an important cell type during the interferon a/b-dependent initiation of autoimmune lupus. These results are important for the development of therapeutic targets for treatment of SLE.
37. Asherson RA, Cervera R, Lahita RG. Latent, incomplete or lupus at all? J Rheumatol 1991; 18:1783-1786.
38. Cervera R, Khamashta MA, Hughes GR. ' Overlap' syndromes. Ann Rheum Dis 1990; 49:947-948.
39. Alarcon GS, Will iams GV, Singer JZ, et al. Early undifferentiated connective tissue disease. I. Early clinical manifestation in a large cohort of patients with undifferentiated connective tissue diseases compared with cohorts of well established connect ive tissue disease. J Rheumatol 1991; 18:1332-1339.
40. Cooper GS. Unraveling the etiology of systemic autoimmune diseases: peering into the preclinical phase of disease. J Rheumatol 2009; 36:1853-1855.
41. Klareskog L,Gregersen PK,Huizinga TW. Prevention of autoimmune rheumatic disease: state of the art and future perspectives Ann Rheum Dis 2010 69, 2062-2066.
42. Doria A, Zen M, Canova M, et al. SLE diagnosis and treatment: when early is early. Autoimmun Rev 2010; 10:55-60.
43. Deane KD, El-Gabalawy H. Pathogenesis and prevention of rheumatic disease: focus on preclinical RA and SLE. Nature Rev Rheumatol 2014; 10:212-228. This review focuses on the development and progression of preclinical RA and SLE and proposes a framework for understanding and describing the stages of early pathogenesis.
44. Costenbader KH, Schur PH. We need better classification and terminology for ' people at high-risk of or in the process of developing lupus' . Arthr Care Res 2015; 67:593-596. This clearly written review explains observations that have led to the current terminology for pre-SLE and suggests new terminology that can be used for individuals at higher risk of developing SLE.
45. Skyler JS, Greenbaum CJ, Lachin JM, et al. Type 1 Diabetes TrialNet: an international collaborative clinical trials network. Ann N Y Acad Sci 2008; 1150:14-24.
46. Schneider M, Liang MH. Connective tissue diseases: SLE classification: plus ca change, plus c'est la meme chose. Nature Rev Rheumatol 2015; 11:262-264. This commentary outlines conceptual and therapeutic advances and improve ments in the management of SLE disease and discusses potential shortfalls of the SLICC criteria.
47. Amezcua-Guerra LM, Higuera-Ortiz V, Arteaga-Garcia U, et al. Performance of the 2012 SLICC and the 1997 ACR clas sification criteria for systemic lupus erythematosus in a real-life scenario. Arthr Care Res 2014; 37:437-441.
48. Yu C, Gershwin ME, Chang C. Diagnostic criteria for systemic lupus erythematosus: a critical review. J Autoimmun 2014; 48-49:10-13.
49. Carpintero MF, Martinez L, Fernandez I, et al. Diagnosis and risk stratification in patients with anti-RNP autoimmunity. Lupus 2015. doi: 10.1177/0961203315575586. 50.
50. Pons-Estel GJ, Wojdyla D, McGwin G Jr., et al. The American College of Rheumatology and the Systemic Lupus International Collaborating Clinics classifica tion criteria for systemic lupus erythematosus in two multiethnic cohorts: a commentary. Lupus 2014; 23:3-9. This article compares the SLE classification in the LUMINA and GLADEL cohorts using SLICC and ACR criteria and addresses whi ch set of criteria would allow earlier patient classification.
51. Ines L, Silva C, Galindo M, et al. Classification of systemic lupus erythematosus: Systemic Lupus International Collaborating Clinics versus American College of Rheumatology criteria. Arthr Care Res 2015. doi: 10.1002/acr.22539.